Phase IV, Single-Arm, Open-Label Study Evaluating Bone Mineral Density in HIV-1-Infected Adults ≥50 Years Old Switching From EVG/COBI/FTC/TAF (Genvoya) or EVG/COBI/FTC/TDF (Stribild) to ABC/DTG/3TC (Triumeq)
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Abacavir/dolutegravir/lamivudine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms STRUCTR
- 12 Sep 2017 New trial record
- 05 Sep 2017 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified September 2017).